FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Trever G. Bivona, Haley Hieronymus, Joel Parker, Kenneth Chang, Miquel Taron, Rafael Rosell, Philicia Moonsamy, Kimberly Dahlman, Vincent A. Miller, Carlota Costa, Gregory Hannon and Charles L. Sawyers ()
Additional contact information
Trever G. Bivona: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20
Haley Hieronymus: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20
Joel Parker: Expression Analysis, Inc.
Kenneth Chang: Cold Spring Harbor Laboratory, One Bungtown Road
Miquel Taron: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Del Canyet s/n
Rafael Rosell: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Del Canyet s/n
Philicia Moonsamy: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20
Kimberly Dahlman: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20
Vincent A. Miller: Thoracic Medical Oncology, Memorial Sloan-Kettering Cancer Center
Carlota Costa: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Del Canyet s/n
Gregory Hannon: Cold Spring Harbor Laboratory, One Bungtown Road
Charles L. Sawyers: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20

Nature, 2011, vol. 471, issue 7339, 523-526

Abstract: Targeting EGFR in lung cancers A substantial proportion of lung cancers in non-smokers are associated with mutations in EGFR, the gene for the epidermal growth factor receptor. EGFR tyrosine kinase inhibitors such as erlotinib are used to treat such tumours, but not all patients respond and some even develop resistance. Now, an RNA interference screen for modifiers of the EGFR inhibitor response suggests a potential strategy for improving lung cancer therapy. The screen reveals that inhibition of CD95/Fas and NF- B signalling enhances the response to EGRF inhibitors in vitro and in vivo. In patients with lung cancer who are treated with EGFR inhibitors, expression of the NF-κB inhibitor IκB is associated with a better response and longer survival, suggesting that combining NF-κB pathway and EGFR inhibitors may prove clinically useful.

Date: 2011
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature09870 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:471:y:2011:i:7339:d:10.1038_nature09870

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature09870

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().